BACKGROUND AND OBJECTIVES: Watch-and-wait is variably adopted by surgeons and the impact of this on outcomes is unknown. We compared the disease-free survival and organ preservation rates of locally advanced rectal cancer patients treated by expert colorectal surgeons at a comprehensive cancer center. METHODS: This study included retrospective data on patients diagnosed with stage II/III rectal adenocarcinoma from January 2013 to June 2017 who initiated neoadjuvant therapy (either with chemoradiation, chemotherapy, or a combination of both) and were treated by an expert colorectal surgeon. RESULTS: Overall, 444 locally advanced rectal cancer patients managed by five surgeons were included. Tumor distance from the anal verge, type of neoadjuvant therapy, and organ preservation rates varied by treating surgeon. There was no difference in disease-free survival after stratifying by the treating surgeon (p = 0.2). On multivariable analysis, neither the type of neoadjuvant therapy nor the treating surgeon was associated with disease-free survival. CONCLUSIONS: While neoadjuvant therapy type and organ preservation rates varied among surgeons, there were no meaningful differences in disease-free survival. These data suggest that among expert colorectal surgeons, differing thresholds for selecting patients for watch-and-wait do not affect survival.
BACKGROUND AND OBJECTIVES: Watch-and-wait is variably adopted by surgeons and the impact of this on outcomes is unknown. We compared the disease-free survival and organ preservation rates of locally advanced rectal cancer patients treated by expert colorectal surgeons at a comprehensive cancer center. METHODS: This study included retrospective data on patients diagnosed with stage II/III rectal adenocarcinoma from January 2013 to June 2017 who initiated neoadjuvant therapy (either with chemoradiation, chemotherapy, or a combination of both) and were treated by an expert colorectal surgeon. RESULTS: Overall, 444 locally advanced rectal cancer patients managed by five surgeons were included. Tumor distance from the anal verge, type of neoadjuvant therapy, and organ preservation rates varied by treating surgeon. There was no difference in disease-free survival after stratifying by the treating surgeon (p = 0.2). On multivariable analysis, neither the type of neoadjuvant therapy nor the treating surgeon was associated with disease-free survival. CONCLUSIONS: While neoadjuvant therapy type and organ preservation rates varied among surgeons, there were no meaningful differences in disease-free survival. These data suggest that among expert colorectal surgeons, differing thresholds for selecting patients for watch-and-wait do not affect survival.
Authors: Monique Maas; Regina G H Beets-Tan; Doenja M J Lambregts; Guido Lammering; Patty J Nelemans; Sanne M E Engelen; Ronald M van Dam; Rob L H Jansen; Meindert Sosef; Jeroen W A Leijtens; Karel W E Hulsewé; Jeroen Buijsen; Geerard L Beets Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Ane L Appelt; John Pløen; Henrik Harling; Frank S Jensen; Lars H Jensen; Jens C R Jørgensen; Jan Lindebjerg; Søren R Rafaelsen; Anders Jakobsen Journal: Lancet Oncol Date: 2015-07-05 Impact factor: 41.316
Authors: Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila Journal: Lancet Oncol Date: 2015-07-14 Impact factor: 41.316
Authors: Renu R Bahadoer; Esmée A Dijkstra; Boudewijn van Etten; Corrie A M Marijnen; Hein Putter; Elma Meershoek-Klein Kranenbarg; Annet G H Roodvoets; Iris D Nagtegaal; Regina G H Beets-Tan; Lennart K Blomqvist; Tone Fokstuen; Albert J Ten Tije; Jaume Capdevila; Mathijs P Hendriks; Ibrahim Edhemovic; Andrés Cervantes; Per J Nilsson; Bengt Glimelius; Cornelis J H van de Velde; Geke A P Hospers Journal: Lancet Oncol Date: 2020-12-07 Impact factor: 41.316
Authors: James D Smith; Jeannine A Ruby; Karyn A Goodman; Leonard B Saltz; José G Guillem; Martin R Weiser; Larissa K Temple; Garrett M Nash; Philip B Paty Journal: Ann Surg Date: 2012-12 Impact factor: 12.969
Authors: Britt J P Hupkens; Milou H Martens; Jan H Stoot; Maaike Berbee; Jarno Melenhorst; Regina G Beets-Tan; Geerard L Beets; Stéphanie O Breukink Journal: Dis Colon Rectum Date: 2017-10 Impact factor: 4.585
Authors: Andrew G Renehan; Lee Malcomson; Richard Emsley; Simon Gollins; Andrew Maw; Arthur Sun Myint; Paul S Rooney; Shabbir Susnerwala; Anthony Blower; Mark P Saunders; Malcolm S Wilson; Nigel Scott; Sarah T O'Dwyer Journal: Lancet Oncol Date: 2015-12-17 Impact factor: 41.316
Authors: Felipe F Quezada-Diaz; J Joshua Smith; Rosa M Jimenez-Rodriguez; Isaac Wasserman; Emmanouil P Pappou; Sujata Patil; Iris H Wei; Garrett M Nash; Jose G Guillem; Martin R Weiser; Philip B Paty; Julio Garcia-Aguilar Journal: Dis Colon Rectum Date: 2020-07 Impact factor: 4.412